D'souza, U., McGuffin, P. and Buckland, Paul Robert 1997. Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA. Neuropharmacology 36 (11-12) , pp. 1689-1696. 10.1016/S0028-3908(97)00163-9 |
Abstract
A range of antipsychotic drugs, both “typical” and “atypical”, was administered to rats over a time course and at several different dosages. The mRNA levels of dopamine D1 , D2 and D3 receptor were measured in either whole brain or dissected brain regions. D3 receptor mRNA was up-regulated in whole brain by clozapine (10 and 30 but not 3 mg/kg/day), sulphide (50 and 100 but not 20 mg/kg/day), haloperidol (3 but not 1 or 0.3 mg/kg/day), flupenthixol (3 but not 1 or 0.3 mg/kg/day), pimozide (4.5 but not 1.5 or 0.5 mg/kg/day) and loxapine (1.2 and 4 mg/kg/day but not 0.4 mg/kg/day). Sulphide (100 mg/kg/day), clozapine (30 mg/kg/ day) and haloperidol (3 mg/kg/day) all up-regulated the D3 receptor mRNA in nucleus accumbens and olfactory tubercles but not striatum. D1 and D2 receptor mRNA was up-regulated in whole brain by haloperidol and loxapine only, and in the case of haloperidol this was localized to striatum and prefrontal cortex. Haloperidol, clozapine and sulphide all down-regulated D1 mRNA in hippocampus and additionally haloperidol and sulpiride down-regulated it in the cerebellum. This work shows that all the drugs tested upregulated D3 receptor, but effects on D1 and D2 receptors were less general.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Subjects: | R Medicine > R Medicine (General) |
Publisher: | Elsevier |
ISSN: | 0028-3908 |
Last Modified: | 05 Feb 2020 03:39 |
URI: | https://orca.cardiff.ac.uk/id/eprint/57899 |
Citation Data
Cited 33 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |